Literature DB >> 1575214

Adenosquamous carcinoma of the lung. Clinicopathologic and immunohistochemical features.

T Ishida1, S Kaneko, H Yokoyama, T Inoue, K Sugio, K Sugimachi.   

Abstract

Adenosquamous carcinomas (ASC) of the lung comprise only 1.8% of all pulmonary cancers. Eleven patients with this disease (6 men and 5 women; mean age, 62 years [range, 51 to 78 years]) were treated. On the basis of pathologic and immunohistochemical evidence, the tumors were separated into three groups: five ASCs of predominantly glandular type, which may originate from squamous metaplasia in a preexisting adenocarcinoma; three mixed type ASCs, possibly derived from the transition of undifferentiated carcinoma to two different elements; and three predominantly squamous type ASCs resembling high-grade muco-epidermoid carcinoma. The 5-year survival rate of 35% for patients with ASCs was the same as that for patients with other nonsmall cell carcinomas. For two patients with ASCs of the predominantly glandular type and for one with the mixed type, resection was incomplete because of extensive local disease. All tumors of the predominantly squamous type could be excised completely. However, differences in the malignant potential of these three types of ASCs are still controversial.

Entities:  

Mesh:

Year:  1992        PMID: 1575214     DOI: 10.1093/ajcp/97.5.678

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  15 in total

1.  Is the incidence of primary adenocarcinoma of the lung increasing?

Authors:  C J Caldwell; C L Berry
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

2.  Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.

Authors:  Ye Guo; Lin Jia; Guo-Guang Shao; Hong-Wei Sun; Xing-Xing Wang; Guan-Jun Wang; Ke-Wei Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

3.  Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer.

Authors:  Yu-Qian Wang; Qiong-Jie Zhi; Xin-Yue Wang; Dong-Sheng Yue; Kai Li; Ri-Cheng Jiang
Journal:  Oncol Lett       Date:  2017-07-24       Impact factor: 2.967

4.  Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung.

Authors:  H Kanazawa; M Ebina; N Ino-Oka; M Shimizukawa; T Takahashi; S Fujimura; T Imai; T Nukiwa
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

5.  Human papillomavirus DNA in adenosquamous carcinoma of the lung.

Authors:  K Tsuhako; I Nakazato; T Hirayasu; H Sunakawa; T Iwamasa
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

6.  Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.

Authors:  Hidetaka Uramoto; Sohsuke Yamada; Takeshi Hanagiri
Journal:  J Cardiothorac Surg       Date:  2010-10-29       Impact factor: 1.637

7.  Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes.

Authors:  Lewei Zhu; Long Jiang; Jie Yang; Weiquan Gu; Jianxing He
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

8.  Characteristics of lymph node metastasis in resected adenosquamous lung cancer.

Authors:  Min Kong; Jiang Jin; Xiuyu Cai; Jianfei Shen; Dehua Ma; Minhua Ye; Chengchu Zhu; Samuel Freedman; Kelly Walters; Xin Xu; Baofu Chen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Clonal analysis of adenosquamous carcinoma of the lung.

Authors:  S Niho; T Yokose; T Kodama; Y Nishiwaki; K Mukai
Journal:  Jpn J Cancer Res       Date:  1999-11

10.  Resolving Interobserver Discrepancies in Lung Cancer Diagnoses by Spectral Histopathology.

Authors:  Ali Akalin; Ayşegül Ergin; Stanley Remiszewski; Xinying Mu; Dan Raz; Max Diem
Journal:  Arch Pathol Lab Med       Date:  2018-08-24       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.